SEC Comment Letter for REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589) (REGN) — Oct 18, 2016
REGENERON PHARMACEUTICALS, INC. (REGN) (CIK 0000872589)
Date: Oct. 18, 2016 · CIK: 0000872589 · Accession: 0000000000-16-097532
AI Filing Summary & Sentiment
File numbers found in text: 000-19034
Letter
Mail Stop 4546 Octo ber 18, 2016 VIA E -mail Dr. Leonard S. Schleifer, M.D., Ph.D. President and Chief Executive Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road , Tarrytown, New York 10591
Re: Regeneron Pharmaceuticals, Inc. Form 10 -K for Fis cal Year Ended December 31, 2015 Filed February 11, 2016 File No. 000-19034
Dear Dr. Schleifer :
We have comple ted our review of your filing . We remind you that the company and its management are responsible for the accuracy and adequacy of the ir disclosure s, notwithstanding any review, comments, action or absence of action by the staff .
Sincerely,
/s/ Angela M. Connell
Show Raw Text
Mail Stop 4546 Octo ber 18, 2016 VIA E -mail Dr. Leonard S. Schleifer, M.D., Ph.D. President and Chief Executive Officer Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road , Tarrytown, New York 10591 Re: Regeneron Pharmaceuticals, Inc. Form 10 -K for Fis cal Year Ended December 31, 2015 Filed February 11, 2016 File No. 000-19034 Dear Dr. Schleifer : We have comple ted our review of your filing . We remind you that the company and its management are responsible for the accuracy and adequacy of the ir disclosure s, notwithstanding any review, comments, action or absence of action by the staff . Sincerely, /s/ Angela M. Connell Angela M. Connell Accounting Branch Chief Office of Healthcare and Insurance